All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) metastasis (visceral) PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 < 25% PDL1 >25% smoker (current or former) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
urothelial cancer (UC) - bladder cancer (BC), immune chekpoint inhibitors vs. Standard of Care (SoC), meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.83 [0.69; 1.00]
IMvigor-211 (all population), 2018 0.85 [0.73; 0.99]
IMvigor-211 (PDL1>1%), 2018 0.87 [0.72; 1.06]
IMvigor-211 (PDL1>5%), 2018 0.87 [0.63; 1.21]
KEYNOTE-045 (all population), 2017 0.73 [0.59; 0.91]
KEYNOTE-045 (PDL1 CPS >10%), 2017 0.57 [0.37; 0.88]
KEYNOTE-361 (P vs C), 2021 0.92 [0.77; 1.10]
0.84 [0.77 ; 0.90 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017, KEYNOTE-361 (P vs C), 2021 7 0% 4,006 moderate not evaluable deaths (OS) (extension)detailed results IMvigor-211 (all population), 2018 0.82 [0.71; 0.94]
IMvigor-211 (PDL1>5%), 2018 0.87 [0.64; 1.18]
KEYNOTE-045 (all population), 2017 0.70 [0.57; 0.85]
0.79 [0.71 ; 0.88 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 3% 1,707 moderate not evaluable PFS (extension)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.79; 1.16]
0.96 [0.79 ; 1.16 ] KEYNOTE-045 (all population), 2017 1 0% 542 NA not evaluable progression or deaths (PFS)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.82 [0.70; 0.96]
IMvigor-211 (all population), 2018 0.89 [0.60; 1.32]
IMvigor-211 (PDL1>1%), 2018 0.86 [0.53; 1.39]
IMvigor-211 (PDL1>5%), 2018 1.01 [0.76; 1.35]
KEYNOTE-045 (all population), 2017 0.98 [0.81; 1.19]
KEYNOTE-045 (PDL1 CPS >10%), 2017 0.89 [0.61; 1.29]
KEYNOTE-361 (P vs C), 2021 1.35 [1.12; 1.63]
0.98 [0.83 ; 1.15 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017, KEYNOTE-361 (P vs C), 2021 7 65% 4,006 moderate not evaluable CRR detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.96 [1.21; 3.17]
1.96 [1.21 ; 3.17 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 851 NA not evaluable DORdetailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.70 [0.46; 1.08]
IMvigor-211 (all population), 2018 0.16 [0.07; 0.35]
IMvigor-211 (PDL1>1%), 2018 0.20 [0.08; 0.50]
IMvigor-211 (PDL1>5%), 2018 0.16 [0.04; 0.55]
KEYNOTE-045 (all population), 2017 4.66 [1.83; 11.87]
0.45 [0.15 ; 1.37 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 5 90% 738 moderate not evaluable objective responses (ORR)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.15 [0.88; 1.51]
IMvigor-211 (all population), 2018 0.99 [0.68; 1.45]
IMvigor-211 (PDL1>1%), 2018 0.95 [0.61; 1.49]
IMvigor-211 (PDL1>5%), 2018 1.07 [0.58; 2.00]
KEYNOTE-045 (all population), 2017 2.08 [1.29; 3.34]
KEYNOTE-045 (PDL1 CPS >10%), 2017 3.86 [1.43; 10.46]
KEYNOTE-361 (P vs C), 2021 0.53 [0.39; 0.74]
1.15 [0.79 ; 1.67 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017, KEYNOTE-361 (P vs C), 2021 7 81% 4,006 moderate not evaluable objective responses (ORR) (extension)detailed results KEYNOTE-045 (all population), 2017 2.16 [1.34; 3.48]
KEYNOTE-045 (PDL1 CPS >10%), 2017 3.56 [1.30; 9.71]
2.37 [1.54 ; 3.65 ] KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017 2 0% 706 moderate not evaluable AE (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.34 [0.43; 12.83]
IMvigor-211 (all population), 2018 0.38 [0.17; 0.88]
IMvigor-211 (PDL1>5%), 2018 0.67 [0.11; 4.10]
KEYNOTE-045 (all population), 2017 0.28 [0.10; 0.75]
0.50 [0.23 ; 1.09 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 4 38% 2,492 moderate not evaluable AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.92 [0.63; 1.34]
IMvigor-211 (all population), 2018 0.80 [0.62; 1.04]
IMvigor-211 (PDL1>5%), 2018 1.38 [0.81; 2.33]
KEYNOTE-045 (all population), 2017 0.61 [0.43; 0.86]
0.85 [0.64 ; 1.11 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 4 56% 2,492 moderate not evaluable AE (grade 3-5)detailed results KEYNOTE-361 (P vs C), 2021 0.38 [0.26; 0.54]
0.38 [0.26 ; 0.54 ] KEYNOTE-361 (P vs C), 2021 1 0% 644 NA not evaluable AE leading to death (grade 5)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.27 [0.70; 2.27]
IMvigor-211 (all population), 2018 0.91 [0.46; 1.79]
IMvigor-211 (PDL1>5%), 2018 0.73 [0.16; 3.34]
KEYNOTE-045 (all population), 2017 1.59 [0.65; 3.89]
KEYNOTE-361 (P vs C), 2021 3.49 [1.61; 7.56]
1.44 [0.87 ; 2.39 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 5 49% 3,136 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.05 [0.79; 1.40]
IMvigor-211 (all population), 2018 0.37 [0.24; 0.57]
IMvigor-211 (PDL1>5%), 2018 0.44 [0.20; 0.99]
KEYNOTE-045 (all population), 2017 0.63 [0.35; 1.11]
KEYNOTE-361 (P vs C), 2021 0.85 [0.56; 1.29]
0.65 [0.42 ; 1.00 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 5 78% 3,143 moderate not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.85 [0.44; 1.65]
0.85 [0.44 ; 1.65 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable SAE (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.11 [0.85; 1.46]
IMvigor-211 (all population), 2018 0.92 [0.70; 1.19]
IMvigor-211 (PDL1>5%), 2018 1.79 [1.05; 3.05]
1.14 [0.84 ; 1.54 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 60% 1,971 moderate not evaluable STRAE (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.33 [0.99; 1.80]
IMvigor-211 (all population), 2018 0.56 [0.40; 0.78]
IMvigor-211 (PDL1>5%), 2018 0.92 [0.48; 1.80]
KEYNOTE-361 (P vs C), 2021 0.39 [0.26; 0.59]
0.72 [0.40 ; 1.30 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-361 (P vs C), 2021 4 89% 2,615 moderate not evaluable TRAE (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.04 [0.53; 2.03]
IMvigor-211 (all population), 2018 0.28 [0.19; 0.40]
IMvigor-211 (PDL1>5%), 2018 0.38 [0.19; 0.79]
KEYNOTE-045 (all population), 2017 0.17 [0.10; 0.28]
KEYNOTE-361 (P vs C), 2021 0.08 [0.04; 0.14]
0.27 [0.13 ; 0.55 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 5 89% 3,136 moderate not evaluable TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.02 [0.72; 1.43]
IMvigor-211 (all population), 2018 0.33 [0.25; 0.45]
IMvigor-211 (PDL1>5%), 2018 0.55 [0.31; 0.99]
KEYNOTE-045 (all population), 2017 0.19 [0.12; 0.28]
KEYNOTE-361 (P vs C), 2021 0.08 [0.05; 0.12]
0.31 [0.13 ; 0.74 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 5 96% 3,136 moderate not evaluable TRAE leading to death (grade 5)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.96 [0.60; 6.40]
IMvigor-211 (all population), 2018 0.42 [0.13; 1.39]
IMvigor-211 (PDL1>5%), 2018 0.98 [0.14; 7.10]
KEYNOTE-045 (all population), 2017 0.96 [0.24; 3.87]
KEYNOTE-361 (P vs C), 2021 1.13 [0.16; 8.10]
0.95 [0.50 ; 1.80 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 5 0% 3,136 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results IMvigor-211 (all population), 2018 0.22 [0.12; 0.38]
IMvigor-211 (PDL1>5%), 2018 0.37 [0.15; 0.92]
KEYNOTE-045 (all population), 2017 0.48 [0.25; 0.93]
0.33 [0.19 ; 0.55 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 41% 1,649 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
1.53 [0.12 ; 19.99 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 2 0% 1,165 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.01; 5.31]
0.24 [0.01 ; 5.31 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Anaemia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.11 [0.67; 1.84]
IMvigor-211 (all population), 2018 0.40 [0.18; 0.89]
IMvigor-211 (PDL1>5%), 2018 0.98 [0.19; 4.97]
KEYNOTE-045 (all population), 2017 0.07 [0.02; 0.31]
KEYNOTE-361 (P vs C), 2021 0.02 [0.01; 0.07]
0.24 [0.05 ; 1.03 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 5 91% 3,136 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.00 [0.82; 4.92]
IMvigor-211 (all population), 2018 0.42 [0.18; 0.97]
IMvigor-211 (PDL1>5%), 2018 0.49 [0.04; 5.45]
KEYNOTE-045 (all population), 2017 0.13 [0.02; 1.09]
KEYNOTE-361 (P vs C), 2021 0.12 [0.02; 0.98]
0.46 [0.15 ; 1.39 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 5 66% 3,136 moderate not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 5.81 [0.29; 116.49]
KEYNOTE-361 (P vs C), 2021 4.58 [0.51; 41.18]
4.97 [0.85 ; 29.26 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 2 0% 1,165 moderate not evaluable Constipation TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.02 [0.00; 0.38]
IMvigor-211 (PDL1>5%), 2018 0.12 [0.01; 2.28]
KEYNOTE-045 (all population), 2017 0.06 [0.00; 1.02]
KEYNOTE-361 (P vs C), 2021 1.13 [0.16; 8.10]
0.14 [0.02 ; 0.91 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 4 51% 2,293 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.59 [0.27; 25.03]
KEYNOTE-045 (all population), 2017 0.16 [0.01; 3.17]
KEYNOTE-361 (P vs C), 2021 0.38 [0.04; 3.63]
0.63 [0.13 ; 3.13 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 3 20% 2,008 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
2.27 [0.08 ; 67.88 ] KEYNOTE-361 (P vs C), 2021 1 0% 644 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.44 [0.24; 8.71]
KEYNOTE-361 (P vs C), 2021 0.90 [0.24; 3.40]
1.07 [0.37 ; 3.10 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 2 0% 1,165 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.61 [0.70; 9.73]
IMvigor-211 (all population), 2018 0.37 [0.15; 0.88]
IMvigor-211 (PDL1>5%), 2018 2.00 [0.36; 11.15]
KEYNOTE-045 (all population), 2017 0.25 [0.07; 0.92]
KEYNOTE-361 (P vs C), 2021 0.50 [0.15; 1.63]
0.68 [0.29 ; 1.61 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 5 59% 3,136 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.04 [0.00; 0.27]
IMvigor-211 (PDL1>5%), 2018 0.09 [0.01; 1.75]
0.05 [0.01 ; 0.26 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
2.27 [0.08 ; 67.88 ] KEYNOTE-361 (P vs C), 2021 1 0% 644 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
1.04 [0.07 ; 16.70 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 2 0% 1,165 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
2.27 [0.08 ; 67.88 ] KEYNOTE-361 (P vs C), 2021 1 0% 644 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
2.27 [0.08 ; 67.88 ] KEYNOTE-361 (P vs C), 2021 1 0% 644 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
0.96 [0.02 ; 48.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results Out of scale KEYNOTE-361 (P vs C), 2021 0.01 [0.00; 0.13]
0.01 [0.00 ; 0.13 ] KEYNOTE-361 (P vs C), 2021 1 0% 644 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
1.13 [0.02 ; 57.26 ] KEYNOTE-361 (P vs C), 2021 1 0% 644 NA not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.48 [0.02; 14.32]
KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
0.69 [0.05 ; 9.04 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 2 0% 1,165 moderate not evaluable Nausea TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.73 [0.31; 9.49]
KEYNOTE-045 (all population), 2017 0.24 [0.03; 2.13]
KEYNOTE-361 (P vs C), 2021 0.28 [0.06; 1.32]
0.51 [0.14 ; 1.82 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 3 34% 2,008 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 3.86 [0.17; 85.92]
KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
3.03 [0.31 ; 29.97 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 2 0% 1,165 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.01 [1.12; 3.62]
IMvigor-211 (all population), 2018 0.04 [0.01; 0.15]
IMvigor-211 (PDL1>5%), 2018 0.20 [0.04; 0.97]
KEYNOTE-045 (all population), 2017 0.01 [0.00; 0.19]
KEYNOTE-361 (P vs C), 2021 0.00 [0.00; 0.07]
0.07 [0.01 ; 0.83 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 5 92% 3,136 moderate serious Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 4.55 [0.20; 101.37]
4.55 [0.20 ; 101.37 ] KEYNOTE-361 (P vs C), 2021 1 0% 644 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.12 [0.01; 0.95]
IMvigor-211 (PDL1>5%), 2018 0.32 [0.03; 3.14]
KEYNOTE-045 (all population), 2017 0.24 [0.01; 5.31]
0.20 [0.05 ; 0.78 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 0% 1,649 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 9.75 [0.53; 179.40]
KEYNOTE-361 (P vs C), 2021 4.58 [0.51; 41.18]
6.02 [1.04 ; 34.78 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 2 0% 1,165 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.72 [0.06; 51.51]
KEYNOTE-045 (all population), 2017 0.48 [0.02; 14.32]
KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
0.96 [0.12 ; 7.49 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 3 0% 2,008 moderate not evaluable Rash TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.86 [0.02; 43.49]
KEYNOTE-361 (P vs C), 2021 0.57 [0.02; 16.92]
0.68 [0.05 ; 8.83 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, KEYNOTE-361 (P vs C), 2021 2 0% 1,487 moderate not evaluable Sarcoidosis TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
1.13 [0.02 ; 57.26 ] KEYNOTE-361 (P vs C), 2021 1 0% 644 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.32 [0.03; 3.07]
KEYNOTE-361 (P vs C), 2021 1.13 [0.16; 8.10]
0.66 [0.15 ; 2.90 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 2 0% 1,165 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.11 [0.55; 2.26]
KEYNOTE-361 (P vs C), 2021 0.02 [0.00; 0.13]
0.16 [0.00 ; 8.79 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, KEYNOTE-361 (P vs C), 2021 2 93% 1,487 moderate not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
1.57 [0.12 ; 20.47 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 2 0% 1,165 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 0.14 [0.02; 1.12]
0.14 [0.02 ; 1.12 ] KEYNOTE-361 (P vs C), 2021 1 0% 644 NA not evaluable Abdominal pain AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.40 [0.10; 1.58]
0.40 [0.10 ; 1.58 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 2.27 [0.58; 8.88]
2.27 [0.58 ; 8.88 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Alopecia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.16 [0.01; 3.17]
0.16 [0.01 ; 3.17 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Anaemia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.08 [0.82; 1.42]
KEYNOTE-045 (all population), 2017 0.65 [0.37; 1.16]
0.89 [0.56 ; 1.44 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, KEYNOTE-045 (all population), 2017 2 58% 1,364 moderate not evaluable Arthralgia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.16 [0.01; 3.17]
0.16 [0.01 ; 3.17 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Asthenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.43 [0.81; 2.50]
KEYNOTE-045 (all population), 2017 0.14 [0.03; 0.63]
0.50 [0.05 ; 4.78 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, KEYNOTE-045 (all population), 2017 2 88% 1,364 moderate not evaluable Back pain AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.17; 21.35]
1.92 [0.17 ; 21.35 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Blood and lymphatic system disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.15; 0.40]
0.24 [0.15 ; 0.40 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Blood creatinine increased AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.17; 21.35]
1.92 [0.17 ; 21.35 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Cardiac disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.72 [0.16; 3.23]
0.72 [0.16 ; 3.23 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Constipation AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.35 [0.09; 1.34]
0.35 [0.09 ; 1.34 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Cough AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
1.92 [0.06 ; 57.51 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 3.28 [0.89; 12.06]
3.28 [0.89 ; 12.06 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.24; 3.87]
0.96 [0.24 ; 3.87 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Dizziness AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.48 [0.02; 14.32]
0.48 [0.02 ; 14.32 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Dry skin AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
0.96 [0.02 ; 48.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Dysgeusia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
0.96 [0.02 ; 48.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Dyspnoea AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.61 [0.38; 6.80]
1.61 [0.38 ; 6.80 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Endocrine disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 5.81 [0.29; 116.49]
5.81 [0.29 ; 116.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Eye disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 3.86 [0.17; 85.92]
3.86 [0.17 ; 85.92 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Fatigue AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.66 [0.37; 1.17]
KEYNOTE-045 (all population), 2017 0.63 [0.28; 1.42]
0.65 [0.40 ; 1.04 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, KEYNOTE-045 (all population), 2017 2 0% 1,364 moderate not evaluable Febrile neutropenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.76 [0.81; 3.80]
KEYNOTE-045 (all population), 2017 0.02 [0.00; 0.39]
0.25 [0.00 ; 17.01 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, KEYNOTE-045 (all population), 2017 2 88% 1,364 moderate not evaluable Gastrointestinal disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.42 [0.24; 0.75]
0.42 [0.24 ; 0.75 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable General disorders and administration site conditions AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.49 [0.28; 0.86]
0.49 [0.28 ; 0.86 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Headache AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
1.92 [0.06 ; 57.51 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Hypertension AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.22 [1.05; 4.68]
2.22 [1.05 ; 4.68 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
0.96 [0.02 ; 48.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Increase AST AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 11.75 [0.65; 211.40]
11.75 [0.65 ; 211.40 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Increased ALT AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 5.81 [0.29; 116.49]
5.81 [0.29 ; 116.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Infections and infestations AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.22 [0.72; 2.06]
1.22 [0.72 ; 2.06 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Injury, poisoning and procedure AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.45 [0.40; 5.19]
1.45 [0.40 ; 5.19 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Investigations AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.46 [0.26; 0.79]
0.46 [0.26 ; 0.79 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Leucopenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.74 [0.44; 1.24]
0.74 [0.44 ; 1.24 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Metabolism and nutrition disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.07 [0.62; 1.84]
1.07 [0.62 ; 1.84 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Mucosal inflammation AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.03; 2.13]
0.24 [0.03 ; 2.13 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Musculoskeletal and connective tissue disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.36 [0.59; 3.12]
1.36 [0.59 ; 3.12 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Myalgia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
1.92 [0.06 ; 57.51 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Nausea AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.54 [0.23; 1.27]
KEYNOTE-045 (all population), 2017 0.72 [0.16; 3.23]
0.58 [0.28 ; 1.22 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, KEYNOTE-045 (all population), 2017 2 0% 1,364 moderate not evaluable Nervous system disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.27 [0.10; 0.74]
0.27 [0.10 ; 0.74 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Neutropenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.38 [1.03; 1.84]
KEYNOTE-045 (all population), 2017 0.01 [0.00; 0.18]
0.15 [0.00 ; 16.84 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, KEYNOTE-045 (all population), 2017 2 91% 1,364 moderate not evaluable Peripheral neuropathy AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.01; 5.31]
0.24 [0.01 ; 5.31 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.01; 5.31]
0.24 [0.01 ; 5.31 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Pruritus AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.48 [0.02; 14.32]
0.48 [0.02 ; 14.32 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Pyrexia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.64 [0.11; 3.84]
0.64 [0.11 ; 3.84 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Rash AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
1.92 [0.06 ; 57.51 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Renal and urinary disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 2.77 [1.31; 5.84]
2.77 [1.31 ; 5.84 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 07:31 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 11,288,153,157,290,155,154,289,188,189,239,158,252,253,76,238,236,237
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743